Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF).
Sionna Therapeutics has raised $182.0M in total funding. The most recent round was Series C. The last funding was announced in March 2024.
Sionna Therapeutics's investors include RA Capital Management, Perceptive Advisors, OrbiMed, Atlas Venture, The Rise Fund.
Sionna Therapeutics is headquartered in Natick, United States.
Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF).
Sionna Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sionna Therapeutics — Funding & Investors." VCBacked, March 6, 2024, https://www.vcbacked.co/company/sionna-therapeutics. Accessed November 12, 2026.
VCBacked. (2024). Sionna Therapeutics — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/sionna-therapeutics
{{cite web |title=Sionna Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/sionna-therapeutics |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Sionna Therapeutics? Request a listing update